`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`
`MYLAN PHARMACEUTICALS INC.,
`MSN LABORATORIES PRIVATE LTD.,
`and MSN PHARMACEUTICALS INC.,
`
`Petitioner,
`
`v.
`
`BAUSCH HEALTH IRELAND LIMITED,
`
`Patent Owner.
`
`__________________
`
`Case IPR2022-007221
`U.S. Patent No. 7,041,786
`__________________
`
`PATENT OWNER’S UPDATED EXHIBIT LIST
`
`
`
`
`
`
`
`
`1 IPR2023-00016 has been joined with this proceeding.
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`Pursuant to 37 C.F.R. § 42.63(e), Patent Owner Bausch Health Ireland
`
`Limited hereby submits a current listing of Patent Owner Exhibits. Exhibits 2069-
`
`2070 were filed on P-TACTSand served via email to counsel of record for the
`
`Petitioner.
`
`EXHIBIT
`
`DESCRIPTION
`
`Vol. 37, No. 23, 8498-8507 (1998).
`
`2001
`
`2002
`
`5003
`
`004
`
`3005
`
`2006
`
`2007
`
`2008
`
`Bausch Health Ireland Ltd. et al. v. MSN Lab’ys Private Ltd. et al.,
`Civil Action No. 2:21-cv-10057 (D.N.J.), ECF No. 51, Amended
`Scheduling Order, Entered January 5, 2022.
`
`Bausch Health Ireland Ltd. et al. v. Mylan Pharms. Inc, Civil Action
`No. 1:22-cv-00020 (N.D. W. Va.), ECF No. 98-1, Parties Proposed
`Scheduling Order Checklists, Submitted May 16, 2022.
`
`MSNDefendants’ First Set of Requests For Production to Plaintiffs
`(Nos. 1-50), Served on January 11, 2022.
`
`Case Docket of Bausch Health Ireland Ltd. et al. v. MSN Lab’ys
`Private Ltd. et al., Civil Action No. 2:21-cv-10057 (D.N.J.)
`
`Mylan Defendants’ First Set of Requests For Production to Plaintiffs
`(Nos. 1-132), Served on May 19, 2022.
`
`MSN’s Notice of Paragraph IV Certification Re: MSN’s Plecanatide
`Tablets, 3mg, U.S. Patent Nos. 7,041,786; 9,610,321: 9,616,097;
`9,919,024; 9,925,231; 10,011,637, Dated March 15, 2021 (Excerpt).
`
`Mylan’s Notice of Paragraph IV Certification Re: Mylan’s
`Plecanatide Tablets, 3mg, U.S. Patent Nos. 7,041,786; 9,610,321;
`9,616,097; 9,919,024; 9,925,231; 10,011,637, Dated March 18, 2021.
`
`Hidaka et al., “In Vitro Disulfide-Coupled Folding of Guanylyl
`Cyclase-Activating Peptide and Its Precursor Protein,” Biochemistry,
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`2015
`
`2016
`
`2017
`
`2018
`
`2019
`
`Hidaka et al., “Dual Function of the Propeptide of Prouroguanylin in
`the Folding of the Mature Peptide,” The Journal of Biological
`Chemistry, Vol. 275, No. 33, 25155-25162 (2000).
`
`topologies: structure and
`two
`Marx et al., “One peptide,
`interconversion dynamics of human uroguanylin isomers,” J. Peptide
`Res. 52, 229-240 (1998).
`
`isomers of human uroguanylin:
`Chino et al., “Topological
`interconversion between biologically active and inactive isomers,”
`FEBS Letters, 421, 27-31 (1998).
`
`Hamra et al., “Uroguanylin: Structure and activity of a second
`endogenous peptide that stimulates intestinal guanylate cyclase,”
`Proc. Natl. Acad. Sci. USA, Vol. 90, 10464-10468 (1993).
`
`Ironwood Press Release, “Ironwood Pharmaceuticals Promotes Dr.
`Mark Currie to Senior Vice President, Chief Scientific Officer, and
`President of R&D,” Dated February 11, 2013.
`
`U.S. Patent No. 7,371,727, titled “Methods and Compositions for the
`Treatment of Gastrointestinal Disorders.”
`
`U.S. Patent No. 7,704,947, titled “Methods and Compositions for the
`Treatment of Gastrointestinal Disorders.”
`
`U.S. Patent No. 7,745,409, titled “Methods and Compositions for the
`Treatment of Gastrointestinal Disorders.”
`
`U.S. Patent No. 8,080,526 titled “Methods and Compositions for the
`Treatment of Gastrointestinal Disorders.”
`
`U.S. Patent No. 8,110,553, titled “Methods and Compositions for the
`Treatment of Gastrointestinal Disorders.”
`
`Brancale et al, “Therapeutically targeting guanylate cyclase-C:
`computational modeling of plecanatide, a uroguanylin analog,”
`Pharma Res Per, Vol. 5, Iss. 2, 1-10 (2017).
`
`3
`
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`2020
`
`2021
`
`2022
`(Served
`Only)
`
`2023
`
`2024
`
`2025
`
`2026
`
`2027
`
`2028
`
`2029
`
`2030
`
`2031
`
`Klodt et al., “Synthesis, biological activity and isomerism of
`guanylate cyclase C-activating peptides guanylin and uroguanylin,”
`J. Peptide Res. 50, 222-230 (1997).
`
`International Publication Number WO 01/25266, titled “Uroguanylin
`as an Intestinal Cancer Inhibiting Agent.”
`
`A file history of EP1379224, titled “Guanylate Cyclase Receptor
`Agonists
`for
`the Treatment of Tissue
`Inflammation and
`Carcinogenesis.”
`CONFIDENTIAL Declaration of Kunwar Shailubhai. (Under Seal
`and Public versions)
`CONFIDENTIAL Declaration of Stephen G. Davies. (Under Seal
`and Public versions)
`CONFIDENTIAL Declaration of Scott A. Waldman. (Under Seal
`and Public versions)
`Transcript of November 1, 2022 Deposition of Blake R. Peterson.
`
`CONFIDENTIAL Shailubhai, K., “SP-304: Stimulation of
`Intracellular cGMP Synthesis in T84 Cells”, Study No. SP-PH-001,
`TRUL00018203-24 (2008). (Under Seal and Public versions)
`CONFIDENTIAL
`Shailubhai, K.,
`“Studies
`on
`SP-304
`Thermostability, pH Dependency and Topoisomeric Stability”, Study
`No. SP-PH-004, TRUL00018260-77 (2008). (Under Seal and
`Public versions)
`Curriculum Vitae of Stephen G. Davies.
`
`Curriculum Vitae of Scott A. Waldman.
`
`“FDA approves Trulance for Chronic Idiopathic Constipation”, FDA
`News Release (January 19, 2017), https://www.fda.gov/news-
`events/press-announcements/fda-approves-trulance-chronic-
`idiopathic-constipation.
`
`4
`
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`2032
`
`2033
`
`2034
`
`2035
`
`2036
`
`2037
`
`2038
`
`2039
`
`2040
`
`2041
`
`Dressman, et al., “Upper Gastrointestinal (GI) pH in Young, Healthy
`Men and Women”, Pharmaceutical Research, Vol. 7, No. 7, 756-61
`(1990).
`
`Nugent, et al., “Intestinal luminal pH in inflammatory bowel disease:
`possible determinants and
`implications
`for
`therapy with
`aminosalicylates and other drugs”, Gut, Vol. 48, No. 4, 571-77
`(2001).
`
`Rudin, “Chapter 4 - Effects of Polymer Isomerism on Conformational
`Changes”, Elements of Polymer Science & Engineering (1999), PP.
`121-153.
`
`Jonson, et al., “A critical view on conservative mutations”, Protein
`Engineering, Vol. 14, No. 6, 397-402 (2001).
`
`Fiser, et al., “Conservation of amino acids in multiple alignments:
`aspartic acid has unexpected conservation”, FEBS Letters, 397, 225-
`229 (1996).
`
`Garcia et al., “Processing and Characterization of Human
`Proguanylin Expressed in Escherichia coli”, Journal of Biological
`Chemistry, Vol. 268, No. 30, 22397-22401 (1993).
`
`Takada et al., “Alternation of a Single Amino Acid in Peroxisome
`Proliferator-Activated Receptor-α (PPARα) Generates a PPARδ
`Phenotype”, Molecular Endocrinology, Vol. 14, No. 5, 733-740
`(2000).
`
`Sood, et al., “Peroral Route: An Opportunity for Protein and Peptide
`Drug Deliveryϯ”, Chem. Rev., Vol. 101, No. 11, 3275-3303 (2001).
`
`Letter from Michael Pennington, Ph.D. to Dr. Kunwar Shailubhai
`(March 31, 2004).
`
`Gastrin”,
`Pure
`a
`of
`“Characterization
`Grossman,
`Gastrin: Proceedings of a Conference Held
`in September
`1964, University of California Press, Los Angeles (1966), Pp. 26-47.
`
`5
`
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`2042
`
`2043
`
`2044
`
`2045
`
`2046
`
`2047
`
`2048
`
`2049
`
`Barrett et al., “Chapter 6: Synthesis of Amino Acids”, Amino Acids
`and Peptides, Cambridge University Press (1998), Pp. 120-129.
`
`Jeng et al., “Direct Measurement of the Aspartic Acid 26 pKa for
`Reduced Escherichia coli Thioredoxin by 13C NMR”, Biochemistry,
`Vol. 35, No. 1, 1-6 (1996).
`
`Nguyen et al., “X-ray and thermodynamic studies of staphylococcal
`nuclease variants I92E and I92K: insights into polarity of the protein
`interior”, Journal of Molecular Biology, Vol. 341, No. 2, 565-74
`(2004).
`
`Harms et al., “The pKa values of acidic and basic residues buried at
`the same internal location in a protein are governed by different
`factors”, Journal of Molecular Biology, Vol. 389, No. 1, 34-47
`(2009).
`
`Liu et al., “In Vivo Imaging of Human Colorectal Cancer Using
`Radiolabeled Analogs of the Uroguanylin Peptide Hormone”,
`Anticancer Research, Vol. 29, 3777-3784 (2009).
`
`Reserved.
`
`Borgaonkar et al., “Quality of life measurement in gastrointestinal
`and liver disorders”, Gut, Vol. 47, Iss. 3, 444-54 (2000).
`
`Francis et al., “The irritable bowel syndrome”, Postgraduate Medical
`Journal, Vol. 73, 1-7 (1997).
`
`2050 Wald, “Chapter 41: Approach to the Patient with Constipation”,
`Textbook of Gastroenterology, (Tadataka Yamada ed., 3rd Ed., Vol.
`1, Lippincott Williams & Wilkins 1999).
`
`2051
`
`2052
`
`Thompson et al., “Functional bowel disorders and functional
`abdominal pain”, Gut, Vol. 45, Suppl. II, II43-7 (1999).
`
`Collins et al., “The putative role of inflammation in the irritable bowel
`syndrome”, Gut, Vol. 49, Iss. 6, 743-5 (2001).
`
`6
`
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`2053
`
`2054
`
`2055
`
`2056
`
`2057
`
`2058
`
`2059
`
`2060
`
`2061
`
`2062
`
`Camilleri et al., “Visceral hypersensitivity: facts, speculations, and
`challenges”, Gut, Vol. 48, Iss. 1, 125-31 (2001).
`
`Suares et al., “Prevalence of, and risk factors for, chronic idiopathic
`constipation in the community: systematic review and meta-
`analysis”, The American Journal of Gastroenterology, Vol. 106, No.
`9, 1582-91 (2011).
`
`Sandler et al., “Demographic and dietary determinants of constipation
`in the US population”, The American Journal of Public Health, Vol.
`80, No.2, 185-9 (1990).
`
`Faigel, “A clinical approach to constipation”, Clinical Cornerstone,
`Vol. 4, Iss. 4, 11-18 (2002).
`
`Zalewski, “Cisapride Withdrawal Requires Alternative Therapy”,
`Cleveland Clinic, Center for Continuing Education, Pharmacotherapy
`Update,
`Vol.
`3,
`No.
`2
`(2000),
`https://www.clevelandclinicmeded.com/medicalpubs/pharmacy/may
`june2000/cisapride.htm.
`
`Bharucha et al., “Mechanisms, Evaluation, and Management of
`Chronic Constipation”, Gastroenterology, Vol. 158, No. 5, 1232-
`1249 (2020).
`
`Chey et al., “Randomized Trial of 2 Delayed-Release Formulations
`of Linaclotide in Patients With Irritable Bowel Syndrome With
`Constipation”, The American Journal of Gastroenterology, Vol. 116,
`Iss. 2, 354-361 (2021).
`
`Carpick et al., “The Escherichia coli heat-stable enterotoxin is a long-
`lived superagonist of guanylin”, Infection and Immunity, Vol. 61, No.
`11, 4710-5 (1993).
`
`Lucas et al., “Guanylyl cyclases and signaling by cyclic GMP”,
`Pharmacological Reviews, Vol. 52, No. 3, 375-413 (2000).
`
`Bełtowski, “Guanylin and related peptides”, Journal of Physiology
`and Pharmacology, Vol. 52, No. 3, 351-75 (2001).
`
`7
`
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`Reserved.
`
`Trulance® Label (October 2020).
`
`Kita et al., “Characterization of human uroguanylin: a member of the
`guanylin peptide family”, The American Journal of Physiology, Vol.
`266, Iss. 2, F342-8 (1994).
`
`Supplemental Declaration of Kunwar Shailubhai
`
`Supplemental Declaration of Stephen G. Davies, D. Phil.
`
`Supplemental Declaration of Scott A. Waldman, M.D., Ph.D., FDP,
`FAHA, FNAL, FASPET
`
`Deposition Transcript of Blake R. Peterson, Ph.D., dated April 25,
`2023
`
`2063
`
`2064
`
`2065
`
`2066
`(Served
`Only)
`
`2067
`(Served
`Only)
`
`2068
`(Served
`Only)
`
`2069
`
`2070
`
`Deposition Transcript of Michael Samuel Epstein, M.D., dated April
`11, 2023
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`Date: May 15, 2023
`
`
`
`
`/Justin J. Hasford/
`By:
`Justin J. Hasford, Reg. No. 62,180
`Lead Counsel
`Bryan C. Diner, Reg. No. 32,409
`Back-up Counsel
`Joshua L. Goldberg, Reg. No. 59,369
`Back-up Counsel
`Kassandra M. Officer Reg. No. 74,083
`Back-up Counsel
`Lauren J. Robinson Reg. No. 74,100
`8
`
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`Back-up Counsel
`Caitlin E. O’Connell, Reg. No. 73,934
`Back-up Counsel
`Kyu Yun Kim, Reg. No. 72,783
`Back-up Counsel
`
`FINNEGAN, HENDERSON, FARABOW,
` GARRETT & DUNNER, L.L.P.
`901 New York Ave. NW
`Washington, DC 20001-4413
`(202) 408-4000
`
`Counsel for the Patent Owner
`
`9
`
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Patent Owner’s
`
`Updated Exhibit List and Exhibits 2069-2070 served electronically via email on
`
`May 15, 2023, to counsel of record for the Petitioner at the following:
`
`Jad A. Mills
`Wilson Sonsini Goodrich & Rosati PC
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104-7036
`jmills@wsgr.com
`
`Richard Torczon
`Tasha M. Thomas
`Wilson Sonsini Goodrich & Rosati PC
`1700 K Street N.W., 5th Floor
`Washington, DC 20006
`rtorczon@wsgr.com
`tthomas@wsgr.com
`
`
`Dennis D. Gregory
`Wilson Sonsini Goodrich & Rosati PC
`900 South Capital of Texas Highway, Las Cimas IV, Fifth Floor
`Austin, TX 78746-5546
`dgregory@wsgr.com
`
`4863-5899-2145@mail.vault.netdocuments.com
`
`Andrew O. Larsen
`Merchant & Gould, P.C.
`500 Fifth Avenue, Suite 4100
`New York, NY 10110
`alarsen@merchantgould.com
`
`
`
`
`
`
`
`
`
`Case No. IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`Melissa Hayworth
`Merchant & Gould, P.C.
`1900 Duke, Street, Suite 600
`Alexandria, VA 22314
`mhayworth@merchantgould.com
`
`Christopher J. Sorenson
`Merchant & Gould, P.C.
`150 South Fifth Street, Suite 2200
`Minneapolis, MN 55402
`csorenson@merchantgould.com
`
`plecanatidemerchant@merchantgould.com
`
`
`
`
`Dated: May 15, 2023
`
`
`
`
`
`
`
`
`
`
`
`/Geneva Eaddy/
`Geneva Eaddy
`Case Manager
`FINNEGAN, HENDERSON, FARABOW,
` GARRETT & DUNNER LLP
`
`
`
`
`
`
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
